Receives Import and Export licenses and
Commences Shipment to Luxembourg Market
TSX | NYSE: ACB
EDMONTON, Dec. 6, 2018 /PRNewswire/ - Aurora Cannabis
Inc. ("Aurora" or the "Company") (NYSE: ACB) (TSX: ACB)
(Frankfurt: 21P; WKN: A1C4WM)
announced today that the company, through its wholly owned
subsidiary Aurora Europe GmbH, has been selected by the Luxembourg
Health Ministry for the supply of medical cannabis to that country
and an initial purchase order for approximately 20 kilograms has
been received.
The Company has received all required authorizations (import and
export licenses) and has commenced its first shipment of high-grade
medical cannabis to Luxembourg's
Division de la Pharmacie et des Medicaments, representing the
second time the Company has received an order directly from a
European government.
"To our knowledge, Aurora is the first medical cannabis producer
selected by the Luxembourg Health Ministry to supply dried cannabis
flower," said Neil Belot, Chief
Global Business Development Officer. "This is a reflection of the
trust we have earned with governments and regulators around the
world. We look forward to supplying patients in need in what will
be the 7th European Union member country where we have
exported plants or products to help meet growing patient
demand."
Maximilian Weinberg Head of
Business Development Aurora Europe GmbH, added, "Working directly
with governments provides patients all over Europe the assurance that the medical cannabis
products they consume meet the highest quality and safety
standards. We are proud to be a trusted partner for both
wholesalers and governments throughout Europe, and look forward to further increasing
our footprint in this important growth market in which we have
substantial early mover advantage."
About Aurora
Headquartered in Edmonton, Alberta,
Canada with funded capacity in excess of 500,000 kg per
annum and sales and operations in 22 countries across five
continents, Aurora is one of the world's largest and leading
cannabis companies. Aurora is vertically integrated and
horizontally diversified across every key segment of the value
chain, from facility engineering and design to cannabis breeding
and genetics research, cannabis and hemp production, derivatives,
high value-add product development, home cultivation, wholesale and
retail distribution.
Highly differentiated from its peers, Aurora has established a
uniquely advanced, consistent and efficient production strategy,
based on purpose-built facilities that integrate leading-edge
technologies across all processes, defined by extensive automation
and customization, resulting in the massive scale production of
high quality product at low cost. Intended to be replicable and
scalable globally, our production facilities are designed to
produce cannabis of significant scale, with high quality,
industry-leading yields, and low per gram production costs. Each of
Aurora's facilities is built to meet EU GMP standards, and its
first production facility, the recently acquired MedReleaf Markham
facility, and its wholly owned European medical cannabis
distributor Aurora Deutschland, have achieved this level of
certification.
In addition to Aurora's rapid organic growth and strong
execution on strategic M&A, which to date includes 15 wholly
owned subsidiary companies – MedReleaf, CanvasRX, Peloton
Pharmaceutical, Aurora Deutschland, H2 Biopharma, Urban Cultivator,
BC Northern Lights, Larssen Greenhouses, CanniMed Therapeutics,
Anandia Labs, HotHouse Consulting, MED Colombia, Agropro, Borela,
and ICC – Aurora is distinguished by its reputation as a partner
and employer of choice in the global cannabis sector, having
invested in and established strategic partnerships with a range of
leading innovators, including: Radient Technologies Inc. (TSXV:
RTI), Hempco Food and Fiber Inc. (TSXV: HEMP), Cann Group Ltd.
(ASX: CAN), Micron Waste Technologies Inc. (CSE: MWM), Choom
Holdings Inc. (CSE: CHOO), Capcium Inc. (private), Evio Beauty
Group (private), Wagner Dimas (private), CTT Pharmaceuticals (OTCC:
CTTH), and Alcanna Inc. (TSX: CLIQ).
Aurora's Common Shares trade on the TSX and NYSE under the
symbol "ACB", and are a constituent of the S&P/TSX Composite
Index.
For more information about Aurora, please visit our investor
website, investor.auroramj.com
Terry Booth, CEO
Aurora Cannabis Inc.
Caution Concerning Forward-Looking Statements
This news release includes statements containing certain
"forward-looking information" within the meaning of applicable
securities law ("forward-looking statements"). Forward-looking
statements are frequently characterized by words such as "plan",
"continue", "expect", "project", "intend", "believe", "anticipate",
"estimate", "may", "will", "potential", "proposed" and other
similar words, or statements that certain events or conditions
"may" or "will" occur and include, but are not limited to the
variety of cannabis products that Aurora will supply to the adult
use market.. These statements are only predictions. Various
assumptions were used in drawing the conclusions or making the
projections contained in the forward-looking statements throughout
this news release. Forward-looking statements are based on the
opinions and estimates of management at the date the statements are
made, and are subject to a variety of risks and uncertainties and
other factors that could cause actual events or results to differ
materially from those projected in the forward-looking statements.
The Company is under no obligation, and expressly disclaims any
intention or obligation, to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise, except as expressly required by applicable law.
Neither the TSX, NYSE nor their Regulation Services
Provider (as that term is defined in the policies of the TSX and
NYSE) accepts responsibility for the adequacy or accuracy of this
release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/aurora-increases-eu-footprint-with-medical-cannabis-shipment-to-luxembourg-300761480.html
SOURCE Aurora Cannabis Inc.